Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Bioengineering aims to improve targeted cancer therapies by enhancing drug delivery, boosting immune responses, and refining surgical techniques. The field is highly interdisciplinary, merging ...

Recent advancements in nanotechnology have paved the way for innovative approaches in the fight against cancer. Scientists have unveiled groundbreaking cancer-fighting nanobots, promising a revolution ...

Lung cancer in never-smokers exhibits distinct biological characteristics, often leading to late-stage diagnoses due to lack of screening. Targeted therapies, guided by molecular testing, offer ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

India's oncology market is shifting to precision medicine as CDSCO approvals expand immunotherapies, ADCs and targeted ...

A $10 million grant by retired biotechnology leader and trustee board member Henri A. Termeer will help Massachusetts General Hospital in Boston build the Henri and Belinda Termeer Center for Targeted ...

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

Triple-positive breast cancer involves tumors positive for estrogen, progesterone, and HER2 receptors, affecting treatment decisions and strategies. Diagnosis includes imaging and biopsy to confirm ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).